<DOC>
	<DOC>NCT00420784</DOC>
	<brief_summary>The PROVE3 trial is a partially double blinded, randomized, Phase 2 research study of an investigational drug, Telaprevir (VX-950) or Placebo, with Pegylated Interferon Alfa 2a (Peg-IFN-alfa-2a, Pegasys速), and Ribavirin (RBV, Copegus速) in people with genotype 1 hepatitis C who have not achieved a Sustained Viral Response (SVR) with a previous treatment of interferon therapy.</brief_summary>
	<brief_title>A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Males and females between 18 and 70 years old Detectable plasma hepatitis C virus (HCV) ribonucleic acid (RNA) greater than or equal to (&gt;=) 10,000 international units per milliliter (IU/mL) Must have chronic hepatitis C (genotype 1) and have already received at least one prior course of pegylated interferon alfa 2a with ribavirin Cannot also be infected with Human Immunodeficiency Virus or hepatitis B Must be judged to be in general good health and able to receive Pegasys速 and Copegus速 No drug or alcohol abuse in the last year Must agree to use two effective methods of birth control during the study and for 6 months after you stop taking study medication. One of the methods needs to be a 'barrier' method (condom or diaphragm) If you are a woman, you cannot be in this study if you are pregnant or nursing Participation in any clinical trial of a HCV protease inhibitor of any duration Prior response to therapy and failure to achieve SVR which was due to treatment noncompliance Any other cause of significant liver disease in addition to hepatitis C; this may include but is not limited to, hepatitis B, drug or alcoholrelated cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, nonalcoholic steatohepatitis, or primary biliary cirrhosis Diagnosed or suspected hepatocellular carcinoma History of or current evidence of decompensated liver disease Participation in any clinical trial of an investigational drug within 90 days before drug administration or participation in more than 2 drug studies in the last 12 months (exclusive of the current study)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Genotype 1</keyword>
</DOC>